Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.32 |
| ▸ | ITGAV | P06756 | 4/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.32 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.32 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17492912 | 1.00 | KIFC1 (0.33) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL17532369 | 0.93 | ITGA4 (0.35) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL22167488 | 0.93 | ITGA4 (0.35) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL17532361 | 0.93 | MME (0.33) | MMEPSMB10PSMB2 | |
| SCHEMBL19695867 | 0.93 | KIFC1 (0.34) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL17532368 | 0.93 | KIFC1 (0.34) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL17468487 | 0.93 | KIFC1 (0.34) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL22167479 | 0.92 | KIFC1 (0.35) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL17539189 | 0.92 | KIFC1 (0.35) | KIFC1ITGB1ITGA4ITGB7ITGB3 | |
| SCHEMBL22167414 | 0.92 | KIFC1 (0.33) | KIFC1ITGB1ITGA4ITGB7ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KIFC1 4760/4885ITGB1 2411/4885ITGA4 3987/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KIFC1 4760/4885ITGB1 2411/4885ITGA4 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.